Efficiency of recombinant bacille calmette-guérin in inducing humoral and cell mediated immunities against human immunodeficiency virus type 1 third variable domain in immunized mice

Yonsei Medical Journal

Volumn 52, Issue 1, 2011, Pages 173-180

  Kim, Young Jae ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Hiv 1 vaccine; Immunized animal; Recombinant bcg; V3 domain

Indexed keywords

ANTIBODY; BCG VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G2A ANTIBODY; RECOMBINANT MV3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; EXPERIMENTAL GUINEA PIG; EXPRESSION VECTOR; FEMALE; GENE CONSTRUCT; GENE EXPRESSION; GENETIC STABILITY; HEAT SHOCK; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; RECOMBINANT PLASMID; SPLEEN; T LYMPHOCYTE;

AIDS VACCINES; ANIMALS; BCG VACCINE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; GUINEA PIGS; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MICE; MICE, INBRED BALB C;

EID: 78650524677     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2011.52.1.173     Document Type: Article

References (37)

1. Javaherian K, Langlois AJ, LaRosa GJ, Profy AT, Bolognesi DP, Herlihy WC, et al. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science 1990; 250: 1590-3.
2. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996; 85: 1135-48.
3. Sullivan N, Sun Y, Sattentau Q, Thali M, Wu D, Denisova G, et al. CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J Virol 1998; 72: 4694-703.
4. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381: 661-6.
5. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996; 384: 179-83.
6. Speck RF, Wehrly K, Platt EJ, Atchison RE, Charo IF, Kabat D, et al. Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol 1997; 71: 7136-9.
7. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272: 872-7.
8. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993; 261: 1179-81.
9. Emini EA, Putney SD. Human immunodeficiency virus. Biotechnology 1992; 20: 309-26.
10. Shioda T, Oka S, Ida S, Nokihara K, Toriyoshi H, Mori S, et al. A naturally occurring single basic amino acid substitution in the V3 region of the human immunodeficiency virus type 1 env protein alters the cellular host range and antigenic structure of the virus. J Virol 1994; 68: 7689-96.
11. Wolfs TF, Zwart G, Bakker M, Valk M, Kuiken CL, Goudsmit J. Naturally occurring mutations within HIV-1 V3 genomic RNA lead to antigenic variation dependent on a single amino acid substitution. Virology 1991; 185: 195-205.
12. Fomsgaard A, Nielsen HV, Bryder K, Nielsen C, Machuca R, Bruun L, et al. Improved humoral and cellular immune responses against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted intothe hepatitis B surface antigen. Scand J Immunol 1998; 47: 289-95.
13. Mrsny RJ, Daugherty AL, Fryling CM, FitzGerald DJ. Mucosal administration of a chimera composed of Pseudomonas exotoxin and the gp120 V3 loop sequence of HIV-1 induces both salivary and serum antibody responses. Vaccine 1999; 17: 1425-33.
14. Lu Y, Xiao Y, Ding J, Dierich M, Chen YH. Immunogenicity of neutralizing epitopes on multiple-epitope vaccines against HIV-1. Int Arch Allergy Immunol 2000; 121: 80-4.
15. Stover CK, de la Cruz VF, Bansal GP, Hanson MS, Fuerst TR, Jacobs WR Jr, et al. Use of recombinant BCG as a vaccine delivery vehicle. Adv Exp Med Biol 1992; 327: 175-82.
16. Stover CK, de la Cruz VF, Fuerst TR, Burlein JE, Benson LA, Bennett LT, et al. New use of BCG for recombinant vaccines. Nature 1991; 351: 456-60.
17. Choi BK, Cho SH, Bai GH, Kim SJ, Hyun BH, Choe YK, et al. Prevention of encephalomyocarditis virus-induced diabetes by live recombinant Mycobacterium bovis bacillus Calmette-Guérin in susceptible mice. Diabetes 2000; 49: 1459-67.
18. Connell ND, Medina-Acosta E, McMaster WR, Bloom BR, Russell DG. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guérin expressing the Leishmania surface proteinase gp63. Proc Natl Acad Sci U S A 1993; 90: 11473-7.
19. Li F, Horton H, Gilbert PB, McElrath JM, Corey L, Self SG. HIV-1 CTL-based vaccine immunogen selection: antigen diversity and cellular response features. Curr HIV Res 2007; 5: 97-107.
20. Mölder T, Adojaan M, Kaldma K, Ustav M, Sikut R. Elicitation of broad CTL response against HIV-1 by the DNA vaccine encoding artificial multi-component fusion protein MultiHIV--study in domestic pigs. Vaccine 2009; 28: 293-8.
21. Yang OO. Retracing our STEP towards a successful CTL-based HIV-1 vaccine. Vaccine 2008; 26: 3138-41.
22. Ratner L, Haseltine W, Patarca R, Livak KJ, Starcich B, Josephs SF, et al. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 1985; 313: 277-84.
23. Honda M, Matsuo K, Nakasone T, Okamoto Y, Yoshizaki H, Kitamura K, et al. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. Proc Natl Acad Sci U S A 1995; 92: 10693-7.
24. Sell S, Hsu PL. Delayed hypersensitivity, immune deviation, antigen processing and T-cell subset selection in syphilis pathogenesis and vaccine design. Immunol Today 1993; 14: 576-82.
25. Kohm AP, Sanders VM. Suppression of antigen-specific Th2 cell-dependent IgM and IgG1 production following norepinephrinedepletion in vivo. J Immunol 1999; 162: 5299-308.
26. Martin RM, Lew AM. Is IgG2a a good Th1 marker in mice? Immunol Today 1998; 19: 49.
27. Yu XF, Wang Z, Beyrer C, Celentano DD, Khamboonruang C, Allen E, et al. Phenotypic and genotypic characteristics of human immunodeficiency virus type 1 from patients with AIDS in northern Thailand. J Virol 1995; 69: 4649-55.
28. Zvi A, Kustanovich I, Hayek Y, Matsushita S, Anglister J. The principal neutralizing determinant of HIV-1 located in V3 of gp120 forms a 12-residue loop by internal hydrophobic interactions. FEBS Lett 1995; 368: 267-70.
29. Isaka Y, Sato A, Miki S, Kawauchi S, Sakaida H, Hori T, et al. Small amino acid changes in the V3 loop of human immunodeficiency virus type 2 determines the coreceptor usage for CXCR4 and CCR5. Virology 1999; 264: 237-43.
30. Brander C, Walker BD. T lymphocyte responses in HIV-1 infection: implications for vaccine development. Curr Opin Immunol 1999; 11: 451-9.
31. Flynn JL. Recombinant BCG as an antigen delivery system. Cell Mol Biol (Noisy-le-grand) 1994; 40 Suppl 1: 31-6.
32. Shen Y, Shen L, Sehgal P, Huang D, Qiu L, Du G, et al. Clinical latency and reactivation of AIDS-related mycobacterial infections. J Virol 2004; 78: 14023-32.
33. Falk LA, Goldenthal KL, Esparza J, Aguado MT, Osmanov S, Ballou WR, et al. Recombinant bacillus Calmette-Guérin as a potential vector for preventive HIV type 1 vaccines. AIDS Res Hum Retroviruses 2000; 16: 91-8.
34. McKinney DM, Skvoretz R, Livingston BD, Wilson CC, Anders M, Chesnut RW, et al. Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL. J Immunol 2004; 173: 1941-50.
35. Berzofsky JA, Ahlers JD, Derby MA, Pendleton CD, Arichi T, Belyakov IM. Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections. Immunol Rev 1999; 170: 151-72.
36. Shibuya K, Robinson D, Zonin F, Hartley SB, Macatonia SE, Somoza C, et al. IL-1 alpha and TNF-alpha are required for IL-12-induced development of Th1 cells producing high levels of IFN-gamma in BALB/c but not C57BL/6 mice. J Immunol 1998; 160: 1708-16.
37. Aguilar D, Infante E, Martin C, Gormley E, Gicquel B, Hernandez Pando R. Immunological responses and protective immunity against tuberculosis conferred by vaccination of Balb/C mice with the attenuated Mycobacterium tuberculosis (phoP) SO2 strain. Clin Exp Immunol 2007; 147: 330-8.